AlzeCure Pharma (ALZCUR) ABGSC Investor Days summary

Strategic focus and business model

• Focuses on developing therapies for Alzheimer's disease and pain, targeting high unmet medical needs and large market potential.

• Operates as a research and development company, advancing projects through early clinical phases before out-licensing or partnering.

• Generates revenue through upfront payments, milestone payments, and royalties.

• Supported by grants, including a €2.5M European Innovation Council grant for a Phase IIa Alzheimer's trial.

• Led by a team with extensive pharmaceutical experience, including former global heads of R&D at major pharma companies.

Pipeline and clinical progress

• Pipeline includes three platforms: NeuroRestore® (cognitive disorders), Alzstatin® (preventive Alzheimer's therapy), and PainLess (pain management).

• NeuroRestore® (ACD856) is a positive allosteric modulator of Trk receptors, showing safety, tolerability, and CNS target engagement in Phase I; Phase IIa in Alzheimer's is grant-financed and upcoming.

• Alzstatin® is a gamma-secretase modulator targeting amyloid production, with preclinical data showing reduction and regression of toxic amyloid plaques; Phase I is ongoing.

• PainLess platform includes ACD137 (TrkA NAM for osteoarthritis and pain, preclinical) and ACD440 (TRPV1 antagonist for neuropathic pain, positive Phase IIa results, orphan drug status in US/EU).

• Multiple candidates and platforms increase the chance of clinical and commercial success.

Scientific and clinical highlights

• NeuroRestore® enhances BDNF and NGF signaling, improving neuronal function and cognition, with potential disease-modifying effects.

• Alzstatin® reduces toxic Aβ42 and increases protective Aβ37/38, with preclinical evidence of plaque regression and prevention.

• ACD440 demonstrated significant pain reduction (~50%) in chronic neuropathic pain patients and is well tolerated as a topical gel.

• Regulatory momentum for ACD440 includes orphan drug designation and positive FDA feedback for pivotal trials.

• The company is positioned as a fast follower to major industry players, with validation from ongoing studies by Roche and others.